Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEBBLE: Extended vs Intermittent Infusion of Beta-lactams in Pediatric Sepsis
NCT07484633Phase 4Not yet recruiting
- Sponsor
- Semmelweis University
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised trial of meropenem, piperacillin + tazobactam, cefepime and ceftriaxone in sepsis and bacterial infection (2 arms), sponsored by Semmelweis University. Primary endpoint: Proportion of patients achieving PK/PD index: 100% fT>MIC (Ctrough >MIC). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
meropenempiperacillin + tazobactamcefepimeceftriaxone
03
Conditions
sepsisbacterial infection
Beyond the preview
Go deeper on NCT07484633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07484633.